Shari Goldfarb, MD

Assistant Attending Physician

Shari Goldfarb, MD

Assistant Attending Physician
Shari Goldfarb, Assistant Attending Physician

Office Phone



SUNY Upstate Medical University, Syracuse; Residency: New York University Medical Center; Fellowship: Memorial Sloan Kettering Cancer Center

Current Research Interests

Dr. Goldfarb’s research focuses on supportive care and survivorship research to improve outcomes in women with breast cancer and survivors of the disease. Specifically, her research focuses on characterizing and improving the negative effects of breast cancer therapy on women’s quality of life with an emphasis on sexual health, fertility and hair preservation. She is currently developing methods to better identify and understand symptoms impacting cancer patients and their overall quality of life. This involves assessment of biomarkers of ovarian reserve, development of novel therapeutic interventions for sexual dysfunction, development of instruments to better measure sexual health and assessment of better strategies to prevent chemotherapy induced alopecia. Dr. Goldfarb’s work integrates clinical trial methods as well as health outcomes research. Her work has been published in multiple journals some of which are The Journal of Sexual Medicine, Ann Surg Oncol, Breast Cancer Res Treat, Clinical Breast Cancer and Seminars of Oncology. She has presented her work at national and international conferences including the American Society of Clinical Oncology, the San Antonio Breast Cancer Symposium, the Multinational Association of Supportive Care in Cancer, and the International Society for the Study of Women’s Sexual Health. Her research is funded by a grant from the Susan G. Komen Breast Cancer Foundation. In addition to her research, Dr. Goldfarb is a practicing medical oncologist whose clinical work focuses on women with breast cancer.


Yarosh DB, Cruz PD, Dougherty I, Bizios N, Kibitel J, Goodtzova K, Both D, Goldfarb S, Green B, Brown D.  FRAP DNA-dependent protein kinase mediates a late signal transduced from ultraviolet-induced DNA damage. J Invest Dermatol. 2000 May; 114(5):1005-10.

Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs M, Witmer M, Van Gorp WG, Fornier M, D’Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie V, Theodoulou M, Norton L, and Hudis C. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient’s perspective. Breast Cancer ResTreat. 2006 Aug; 98:343-348.

Horwitz S, Foss F, Goldfarb S, Molina A, Hamlin P, O’Connor O, Cammarata M, Moskowitz  C and Zelenetz A. FDG-PET scans as a staging study for T-cell lymphomas: high rates of positivity do not result in frequent changes in stage. Blood. Nov 2006; 108:a2399.

Basch E, Goldfarb S. Electronic patient-reported outcomes (ePROs) for collecting sensitive information from patients. J Support Oncol. 2009.

Goldfarb S, Dickler M. Commentary on Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.  Breast Diseases: A Year Book Quarterly. Vol 20(3), October 2009 (in press).

Goldfarb S, Traina T, Dickler M.  Bevacizumab in advanced breast cancer.  Women’s Health. November 2009 (in press).

Ethan Basch, Xiaoyu Jia, Glenn Heller, Allison Barz, Laura Sit, Michael Fruscione, Mark Appawu, Alexia Iasonos, Thomas Atkinson, Shari Goldfarb, Ann Culkin, Mark G. Kris, and Deborah Schrag. Adverse Symptom Event Reporting by Patients versus Clinicians: Relationships with Clinical Outcomes.  JNCI. 2009 (in press).